2021
Lead Investigational Drug Demonstrates Key Improvement
Half Year Accounts and Appendix 4D
PYC Expands US Executive Leadership Team
Progress US Clinical Stage Company and Corporate Objectives
PYC to Participate in RNA Discussion – BIO CEO Conference
December 2020 Quarterly Report and Cashflow
ICR Conference Presentation
PYC to Present at ICR Westwicke Conference
2020
Letter to Shareholders from the US CEO
Appointment of Chief Executive Officer in the United States
Change in substantial holding – Change in substantial holding
Retail Entitlement Offer Share Issue and Appendix 2A
Completion of Retail Entitlement Offer
New Drug for Substantial Unmet Need Added to Pipeline
Technical Presentation – October 2020
Notice of Directors intention not to seek re election at AGM
Investor Call 15th Oct 2020 12pm AEDT 9am AWST
Cancellation of Unlisted Options
PYC’s Lead Drug Effective in Patient Derived Models Tested
Notice of Annual General Meeting:Proxy Form
Corporate Governance Statement and Appendix 4G
Annual Report to shareholders
Second Potential Blockbuster Drug Added to PYC’s Pipeline
Annual Financial Statements June 2020
Creation of Novel Gene Therapy Delivery Technology
Appendix 4E Preliminary Final Report
Appointment of world-renowned Chief Scientific Officer
Shareholder Update August 2020
Shareholder Update – Forward View 2020 Milestones
Investor Call – 8am AWST – Wednesday 12 August 2020
June 2020 Quarterly Activity Report and Cashflow
Successful Dose Response & Toxicity Studies in Lead Program
Change of Director’s Interest Notice x 2
Change in substantial holding
PYC Recruits High Profile Chief Medical Officer to US Ops
World Class Results – Lions Eye Institute News Release
March 2020 Quarterly Activities and Cash Flow Report
Efficacy and Toxicity Studies Presentation
Successful Toxicity Results Confirm Safety Advantage
Investor Call 9.00am AWST Wed 1 April 2020
Becoming a substantial holder
Half Yearly Report and Accounts
NHMRC Grand for Identifying new Antisense Drugs
Visual Evidence of Lead Drugs Efficacy
Initial Director’s Interest Notice
CEO Appointment & Establishment of US Office
Investor Call 27 February 2020
2019
Quarterly Shareholder Update
Drug Delivery Greater than 100% more Effective – Amended
Change in Director’s Notice x 2
Change in Substantial Holding_v2
Change in Substantial Holding
Drug Delivery Greater than 100%
2019 AGM Chairman’s Address
Change in Substantial Holding
Completion of Retail Entitlement Offer
Conclusion of Genentech Antimicrobial Collaboration
PYC Increases Shareholding in Vision Pharma
Change in Substantial Holding
Change of Director’s Interest Notice
Change in Substantial Holding
Entitlement Offer – Investor Presentation
Notice Under Section 708AA
$26.8M Fully Underwritten accelerated Entitlement Offer
Quarterly Shareholder Update and Appendix 4C
Corporate Governance Statement
Drug Delivery Greater than 100%
Annual Report to Shareholders
Notice of Annual General Meeting : Proxy Form
Investor Relations Presentation
Presentation Oligonucleotide Therapeutics Society Meeting
Succesfful Major Milestone – Human Retina in a Dish Model
Strategic Partnership and Lead Program
Successful Time-Course Studies in Animals
Full Year Statutory Accounts
Scientific Advisory Board Appointment
Investor Relations Presentation
Successful Competitive Drug Evaluation in Animals
Successful Time – Course Studies in Animals
Response to ASX Aware Query
Phylogica’s Technology is Effective in Human Cells
Company Presentation – July 2019
Operational Update and Appendix 4c
Animal Models – 400% Outperformance of Gold Standard
Break Through Animal Model Results
March 2019 Quarterly Operational Update
Change of Director’s Interest Notice
Scientific Advisory Board Appointment